Caribou Biosciences Quarterly Balance Sheets Chart
Quarterly
|
Annual
Caribou Biosciences Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||
| current assets: | |||||||||||
| cash and cash equivalents | 51,162,000 | 104,058,000 | 66,194,000 | 52,744,000 | 58,338,000 | 82,085,000 | 112,146,000 | 147,630,000 | 240,420,000 | 435,310,000 | 129,524,000 |
| marketable securities, short-term | 277,665,000 | 234,430,000 | 193,038,000 | 175,794,000 | 189,325,000 | 211,284,000 | 227,778,000 | 206,101,000 | 135,412,000 | ||
| accounts receivable | 148,000 | 1,133,000 | 766,000 | 1,533,000 | 202,000 | 397,000 | 524,000 | 374,000 | 1,153,000 | 578,000 | 2,000 |
| contract assets | 1,425,000 | 1,658,000 | 1,481,000 | 1,639,000 | 2,247,000 | 1,899,000 | 2,093,000 | 1,494,000 | 1,488,000 | 1,853,000 | 830,000 |
| other receivables | 2,286,000 | 2,345,000 | 1,495,000 | 1,670,000 | 2,215,000 | 2,699,000 | 3,094,000 | 4,169,000 | 5,483,000 | 5,354,000 | 7,575,000 |
| prepaid expenses and other current assets | 6,155,000 | 7,069,000 | 5,564,000 | 6,110,000 | 7,921,000 | 8,558,000 | 7,293,000 | 8,242,000 | 7,236,000 | 5,952,000 | 5,036,000 |
| total current assets | 338,841,000 | 350,693,000 | 268,538,000 | 239,490,000 | 260,248,000 | 306,922,000 | 352,928,000 | 368,010,000 | 391,192,000 | 449,047,000 | 142,967,000 |
| non-current assets | |||||||||||
| investments in equity securities | 7,753,000 | 7,763,000 | 7,766,000 | 7,683,000 | 7,698,000 | 7,759,000 | 7,728,000 | 7,666,000 | 7,626,000 | 7,626,000 | 7,626,000 |
| marketable securities, long-term | 43,577,000 | 58,219,000 | 33,289,000 | 62,452,000 | 69,373,000 | 49,221,000 | 26,152,000 | 37,092,000 | 37,676,000 | ||
| property and equipment | 18,270,000 | 16,598,000 | 15,429,000 | 12,646,000 | 10,678,000 | 8,959,000 | 8,006,000 | ||||
| operating lease, right of use assets | 22,182,000 | 22,680,000 | 23,206,000 | 23,715,000 | 24,230,000 | 24,626,000 | 25,250,000 | ||||
| other assets | 1,586,000 | 1,568,000 | 1,419,000 | 1,476,000 | 1,538,000 | 1,336,000 | 1,303,000 | 1,464,000 | 975,000 | 810,000 | 3,396,000 |
| total assets | 432,209,000 | 457,521,000 | 349,647,000 | 347,462,000 | 373,765,000 | 398,823,000 | 421,367,000 | 445,997,000 | 442,356,000 | 461,960,000 | 158,397,000 |
| liabilities and stockholders’ equity | |||||||||||
| current liabilities: | |||||||||||
| accounts payable | 3,120,000 | 2,377,000 | 4,433,000 | 2,651,000 | 1,146,000 | 1,228,000 | 426,000 | 1,814,000 | 3,990,000 | 3,482,000 | 4,029,000 |
| accrued expenses and other current liabilities | 21,135,000 | 18,230,000 | 15,901,000 | 12,544,000 | 16,079,000 | 14,638,000 | 14,910,000 | 11,190,000 | 13,136,000 | 13,930,000 | 13,297,000 |
| operating lease liabilities, current | 1,200,000 | ||||||||||
| deferred revenue | 2,847,000 | 2,826,000 | 12,962,000 | 10,883,000 | 9,937,000 | 12,036,000 | 12,642,000 | 12,838,000 | 8,703,000 | 8,746,000 | 8,681,000 |
| total current liabilities | 28,302,000 | 24,572,000 | 34,375,000 | 27,100,000 | 28,128,000 | 28,814,000 | 28,855,000 | 26,667,000 | 25,829,000 | 26,158,000 | 26,007,000 |
| long-term liabilities | |||||||||||
| deferred revenue, net of current portion | 6,102,000 | 6,728,000 | 18,162,000 | 13,911,000 | 15,954,000 | 15,423,000 | 15,626,000 | 17,326,000 | 22,032,000 | 23,022,000 | 24,208,000 |
| mskcc success payments liability | 2,939,000 | 1,256,000 | 1,117,000 | 1,396,000 | 1,651,000 | 3,039,000 | 1,432,000 | 2,484,000 | 4,080,000 | 6,238,000 | |
| operating lease liabilities, non-current | 25,908,000 | ||||||||||
| deferred tax liabilities | 557,000 | 381,000 | 380,000 | 382,000 | 381,000 | 475,000 | 475,000 | 476,000 | 476,000 | 155,000 | 155,000 |
| total liabilities | 63,808,000 | 59,253,000 | 80,189,000 | 69,190,000 | 72,894,000 | 74,709,000 | 73,478,000 | 74,200,000 | 54,531,000 | 57,559,000 | 55,938,000 |
| commitments and contingencies | |||||||||||
| stockholders’ equity | |||||||||||
| common stock | 8,000 | 8,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 6,000 | 1,000 |
| additional paid-in-capital | 667,648,000 | 664,021,000 | 525,366,000 | 504,255,000 | 499,598,000 | 496,369,000 | 493,043,000 | 489,762,000 | 485,748,000 | 483,710,000 | 10,649,000 |
| accumulated other comprehensive income | 30,000 | ||||||||||
| accumulated deficit | -299,285,000 | -264,780,000 | -254,778,000 | -225,259,000 | -197,215,000 | -170,226,000 | -143,579,000 | -116,882,000 | -97,794,000 | -79,315,000 | -58,341,000 |
| total stockholders’ equity | 368,401,000 | 398,268,000 | 269,458,000 | 278,272,000 | 300,871,000 | 324,114,000 | 347,889,000 | 371,797,000 | 387,825,000 | 404,401,000 | |
| total liabilities and stockholders’ equity | 432,209,000 | 457,521,000 | 349,647,000 | 347,462,000 | 373,765,000 | 398,823,000 | 421,367,000 | 445,997,000 | |||
| current assets | |||||||||||
| current liabilities | |||||||||||
| lease liabilities, current | 1,139,000 | 1,079,000 | 1,022,000 | 966,000 | 912,000 | ||||||
| lease liabilities, non-current | 26,316,000 | 26,155,000 | 26,401,000 | 26,780,000 | 26,958,000 | 27,090,000 | 27,238,000 | ||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized at september 30, 2023 and december 31, 2022; no shares issued and outstanding as of september 30, 2023 and december 31, 2022 | |||||||||||
| accumulated other comprehensive loss | -981,000 | -1,136,000 | -730,000 | -1,518,000 | -2,035,000 | -1,581,000 | -1,089,000 | -135,000 | |||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized at june 30, 2023 and december 31, 2022; no shares issued and outstanding as of june 30, 2023 and december 31, 2022 | |||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized at march 31, 2023 and december 31, 2022; no shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||
| deferred rent and lease incentive liability | 2,097,000 | 1,833,000 | 1,570,000 | ||||||||
| other liabilities | 9,000 | 17,000 | 153,000 | 163,000 | |||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized at december 31, 2022 and 2021, respectively; no shares issued and outstanding as of december 31, 2022 and 2021, respectively. | |||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized at september 30, 2022 and december 31, 2021; no shares issued and outstanding as of september 30, 2022 and december 31, 2021, respectively | |||||||||||
| lease liabilities | 877,000 | 825,000 | |||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized at june 30, 2022 and december 31, 2021; no shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively | |||||||||||
| property and equipment - net | 6,016,000 | 4,887,000 | |||||||||
| operating lease, right of use asset | 25,749,000 | ||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 shares authorized at march 31, 2022 and december 31, 2021; no shares issued and outstanding as of march 31, 2022 and december 31, 2021, respectively | |||||||||||
| liabilities, convertible preferred stock, and stockholders’ equity | |||||||||||
| promissory note — ppp loan | |||||||||||
| promissory note — ppp loan, net of current portion | |||||||||||
| convertible preferred stock, par value 0.0001 per share; no shares authorized, issued, and outstanding at december 31, 2021; 7,766,582 shares authorized, issued, and outstanding at december 31, 2020 | |||||||||||
| preferred stock, par value 0.0001 per share, 10,000,000 and no shares authorized at december 31, 2021 and 2020, respectively; no shares issued and outstanding as of december 31, 2021 and 2020, respectively. | |||||||||||
| total liabilities, convertible preferred stock, and stockholders’ equity | 442,356,000 | 461,960,000 | |||||||||
| property and equipment—net | 4,477,000 | 4,408,000 | |||||||||
| convertible preferred stock, par value 0.0001 per share; no shares authorized, issued, and outstanding at september 30, 2021; 7,766,582 shares authorized, issued, and outstanding at december 31, 2020 | |||||||||||
| liabilities, convertible preferred stock, and stockholders’ deficit | |||||||||||
| success payments liability | 3,835,000 | ||||||||||
| convertible preferred stock, par value 0.0001 per share—14,430,622 and 7,766,582 shares authorized at june 30, 2021 and december 31, 2020, respectively; 14,430,522 and 7,766,582 shares issued and outstanding at june 30, 2021 and december 31, 2020, respectively; | 150,150,000 | ||||||||||
| stockholders’ deficit | |||||||||||
| total stockholders’ deficit | -47,691,000 | ||||||||||
| total liabilities, convertible preferred stock, and stockholders’ deficit | 158,397,000 |
We provide you with 20 years of balance sheets for Caribou Biosciences stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Caribou Biosciences. Explore the full financial landscape of Caribou Biosciences stock with our expertly curated balance sheets.
The information provided in this report about Caribou Biosciences stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.